Back to Newsroom

Pharnext announces the nomination of Michel de Rosen, a Pharmaceutical and Biotechnology Industry Leader, to its Board of Directors

PARIS, Dec. 9, 2014Pharnext SAS, today announced the nomination of Michel de Rosen to its board of directors.  The wealth of expertise Michel de Rosen has cultivated during his time as an executive in the pharmaceutical and biotechnology industries will be an asset to Pharnext moving forward.

For nearly 25 years, Michel de Rosen held various executive positions at Rhône-Poulenc, in particular in its pharmaceutical subsidiary Rhône-Poulenc Rorer, now known as Sanofi, and then at ViroPharma.

Click here to read more